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Abstract
Background: Novel sirolimus eluting stents (SES) have shown non-inferior clinical out-
comes when compared to everolimus eluting stents (EES), however only limited preclinical data 
have been published. Therefore, we evaluate vascular response of a new generation biodegrad-
able polymer SES (BP-SES: Alex Plus, Balton) and fluoropolymer EES (EES: Xience Pro, 
Abbott) in the porcine coronary restenosis model.
Methods: A total of 40 stents were implanted with 120% overstretch in coronaries of 17 dom - 
estic swine: 16 BP-SES, 16 EES and 8 bare metal controls (BMS). Following 28 and 90 days, 
coronary angiography and optical coherence tomography (OCT) was performed, animals sac-
rificed and stented segments harvested for pathological evaluation.
Results: At 28 days neointimal thickness in OCT was lowest in the BP-SES when compared 
to EES and BMS (0.18 ± 0.1 vs. 0.39 ± 0.1 vs. 0.34 ± 0.2 mm, respectively; p = 0.04). There 
was no difference in the proportion of malapposed or uncovered struts, although protruding cov-
ered struts were more common in BP-SES (14.8 ± 10% vs. 4.1 ± 4% vs. 3.7 ± 6%; p = 0.03).  
In pathology, the lowest neointimal thickness was confirmed in BP-SES (p < 0.05). The  
inflammation score was significantly lower in BP-SES and EES when compared to BMS  
(0.24 ± 0.1 vs. 0.4 ± 0.1 vs. 0.77 ± 0.4; p < 0.01) whilst EES and BP-SES had higher fibrin 
scores than BMS (1.2 ± 0.4 vs. 1.3 ± 0.3 vs. 0.17 ± 0.2; p < 0.01). At 90 days neointimal coverage 
and thickness in OCT was comparable between groups and healing in histopathology was complete.
Conclusions: New generation, BP-SES show similar vascular healing and biocompatibility 
profile with marginally higher degree of restenosis inhibition, when compared to fluoropolymer 
EES in the porcine coronary restenosis model. (Cardiol J 2016; 23, 6: 657–666)
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Introduction
First generation sirolimus eluting stents (SES) 
although efficient in restenosis inhibition caused 
delayed healing and as a consequence increased 
restenosis and late thrombotic events when com-
pared to second generation drug eluting stents 
(DES) [1–3]. It has been shown that autonomously 
sirolimus and its derivatives (everolimus, zotaroli-
mus) have similar effects on vascular response 
and clinical outcomes [4, 5], therefore it has been 
postulated that the polymer and release kinetics 
were responsible for the negative tissue effect 
and clinical outcomes. The early generation SES 
consisted of non-erodible PEVA/PBMA polymers 
and thick strut profile stent platform which caused 
anaphylactic and inflammatory reactions, resulting 
in impaired vessel healing and ultimately adverse 
thrombotic events [6]. As a result, novel biodegrad-
able polymers as well as low profile, cobalt or plati-
num chromium stent backbones were proposed, 
which resulted in improved vascular response [7]. 
Furthermore, sirolimus elution has been optimized 
to balance between safety and efficacy [8]. These 
technological refinements resulted in non-inferior 
clinical outcomes of second generation SES when 
compared to everolimus eluting stents (EES) in 
large randomized trials [5, 9–11]. However, the 
underlying temporal tissue vascular response, has 
been not well described. Therefore, in this study 
we evaluate in-vivo as well as histopathological 
temporal vascular healing and biocompatibility to 
second generation biodegradable polymer siroli-
mus eluting stents (BP-SES, Alex Plus, Balton) 
and compare it with EES (Xience Pro, Abbott) in 
the experimental setting of a porcine coronary in-
stent restenosis model. 
Methods
Device description
The studied SES (BP-SES, Alex Plus, Balton, 
Poland) employs fully biodegradable multilayer 
structure containing a copolymer of poly-lactic 
and glycolic acid and sirolimus at dose of 1.3 μg/ 
/mm2 (data on file at Balton). The total mass of the 
polymer on a 3.0 × 15 mm stent does not exceed 
360 μg. The experimental studies in the porcine 
in-stent restenosis model at 8 weeks has shown 
nearly full polymer biodegradation and 95% drug 
release of initial drug load [12]. The stent utilizes 
the L605 cobalt chromium alloy platform with strut 
thickness of 70 μm and closed cell design, which 
also served as bare metal control (BMS, Coflexus, 
Balton). The cell area is larger by 50% when com-
pared to predecessor (Alex, Balton, Poland) to 
facilitate easier side branch access. 
Everolimus-eluting stent (Reference group, 
Xience Pro, Abbott, Santa Clara, USA) contains 
the drug at a dose of 100 mg/cm2 of stent surface 
and is coated with a fluoropolymer (poly(vinylidene 
fluoride-co-hexafluoropropylene) designed to re-
lease 80% of the everolimus in the first 30 days 
after deployment. 
Study design
Study flow chart is presented in Figure 1. A total 
of 17 domestic swine of both genders were in-
cluded. All animals ranged from 5 to 7 months 
of age with an average weight of around 45 kg at 
the time of enrolment. Middle arterial segments, 
without side branches of all three coronary arteries 
(RCA, LAD, LCX), screened for stent implanta-
tion. After qualitative coronary angiography (QCA) 
evaluation, 40 segments were eligible for the study 
and 40 stents, including 16 BP-SES (study group), 
16 EES (reference group) and 8 BMS controls were 
implanted after live QCA guidance to ensure 120% 
overstretch. Half of the animals were followed up 
for 28 days and the other half for 3 months. Sub-
sequently control coronary angiography with opti-
cal coherence tomography (OCT) was performed 
and swine sacrificed. All stented segments were 
harvested for pathological analysis. All interven-
tions and analyses were blinded to operators or 
investigators. 
Experimental procedures
The study protocol was approved by the local 
ethics committee for animal research. All ani-
mals received standard care outlined in the study 
protocol and in accordance with the act of animal 
welfare and the “Principles of Care of Laboratory 
Animals” [13]. The experimental protocol has been 
published before [14]. Briefly, the animals were 
loaded with double anti-platelet therapy 3 days 
before intervention. Prior to procedure, swine 
were pre medicated with atropine (0.5 mg) and 
subsequently sedated with intramuscular ketamine 
hydrochloride (20 mg/kg) and xylazine (2 mg/kg), 
intubated, and anesthetized with an intravenous 
propofol bolus (20–40 mg) followed by a con-
tinuous infusion (2–4 mg/kg/h). A vascular sheath 
(6 F) was placed in the right or left femoral artery 
utilizing a Seldinger technique. Anticoagulation 
with heparin was achieved (3,000–10,000 IU) to 
maintain a coagulation time ≥ 250 s. Following 
coronary angiography, all coronary vessels were 
658 www.cardiologyjournal.org
Cardiology Journal 2016, Vol. 23, No. 6
sized for proper stent implantation after live QCA 
analysis. Stent were implanted with a pressure 
ensuring 120% arterial overstretch.
All pigs were anesthetized and prepared in 
the same fashion as described above at 28 days 
and 3 months following stent implantations to 
perform control coronary angiography and OCT. 
Subsequently animals were humanely sacrificed 
with pentobarbital overdose.  
Quantitative coronary analysis 
Coronary arteries angiographies were ob-
tained using Siemens Coroskop Millenium Edition 
angiographic unit. Judkins Right, 6 French guiding 
catheter was utilized to obtain coronary angio-
graphy and stent implantation. QCA analysis was 
performed in a blinded fashion utilizing QAngio XA 
Software version 7.1.14.0 (Medis Medical Imaging 
Systems) from two contralateral projections. The 
baseline and 28-day follow-up reference vessel 
diameters (RVD) and minimal lumen diameters 
(MLD) were taken from the treated segments using 
the guiding catheter as a standard for measure-
ment. The balloon-to-artery ratio was calculated. 
Percent diameter stenosis (%DS) at follow-up was 
calculated as: [1 – (MLD/RVD)] × 100%.
Optical coherence tomography 
The OCT images of all tested coronary seg-
ments were acquired at 28 and 90 days follow 
up with a non-occlusive technique using the 
ILUMIEN™ imaging system (St. Jude Medical, St. 
Paul, MN). The OCT catheter was pulled back at 
20 mm/s and OCT images were generated at 
100 frames/s. Contrast media (OMNIPAQUE 350; 
GE Healthcare) was continuously flushed through 
a guiding catheter during imaging catheter pull-
back to ensure blood clearance from the coronary 
arteries. Analysts who were blinded to procedural 
information analyzed all acquired images. Cross-
sectional OCT images were analyzed at 1 mm 
intervals. Reference vessel area was calculated at 
5 mm distance from proximal and distal edge of 
stent. Neointimal thickness was calculated by 
subtracting the luminal cross-sectional areas from 
the stent. The strut appearance and coverage was 
qualified as embedded, protruding covered, pro-
truding uncovered and malapposed according to 
previously described definitions [15, 16].
Histological analysis
Following vessel harvesting, stented seg-
ments were immersed in normal buffered formalin 
10%. Stented artery segments were embedded in 
methyl methacrylate, then divided into a target of 
3 blocks identified as proximal, middle and distal. 
Thin sections (approximately 8 μm) from each 
stented artery block were stained with hematoxylin 
and eosin (H&E) and Verhoeff-van Gieson (VVG). 
Images of each VVG-stained artery section (low 
magnification, whole section) were digitally cap-
tured. VVG-stained stented artery sections were 
examined by a trained operator for histomorpho-
metry. All H&E and VVG stained artery sections 
Figure 1. Study schematics; ISR — in-stent restenosis; BP-SES — biodegradable polymer sirolimus eluting stent; 
BMS — bare metal stent; EES — everolimus eluting stent. 
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were examined by the study pathologist for semi-
quantitative and descriptive histopathology.
VVG-stained stented artery sections were 
examined using light microscopy, image capture, 
and quantitative morphometric computer-assisted 
methods with Image Pro Plus 6.1.0.346 software. 
For each section, the operator delineated the ex-
ternal elastic lamina (EEL — at the junction of the 
medial and adventitial layers), the internal elastic 
lamina (IEL — at the junction of the medial and 
neointimal layers), and the luminal border. Neo-
intimal thickness was measured as the distance 
from the inner surface of the stent struts to the 
luminal border. The following measures were used 
to calculate vessel layer areas: Media = EEL–IEL; 
Neointima = IEL–Lumen; % Area Stenosis = 
= [1 – (Lumen area / IEL area)] × 100. 
Semi-quantitative microscopic evaluation of 
stented artery sections was performed. Scores 
were assigned to each stented section using the 
criteria listed below. Unstented sections were ex-
amined and significant observations were graded 
(when appropriate) and reported. All sections 
were evaluated using semi-quantitative scoring 
criteria. To evaluate the amount of injury, a crite-
ria defined by Schwartz et al. [17] were utilized: 
0 = IEL intact, 1 = IEL lacerated, 2 = media 
lacerated, 3 = EEL lacerated. To evaluate the 
extent of peri-strut inflammatory reaction the fol-
lowing grade by Kornowski et al. [18] was used: 
0 = minimal inflammatory response around strut, 
1 = few inflammatory cells around strut, 2 = mild 
to moderate inflammation, can extend into but do 
not efface surrounding tissue, 3 = dense and thick 
peri-strut aggregate of inflammatory cells, effacing 
surrounding tissue. Fibrin deposition was graded 
as follows (strut-by-strut): 0 = absent, or rare 
minimal spotting around strut, 1 = fibrin in small 
amounts, localized only around strut, 2 = fibrin 
moderately abundant or denser, extending beyond 
strut, 3 = abundant, dense fibrin, bridging between 
strut. Endothelialisation was assessed with regards 
to percentage coverage of artery circumference: 
0 = < 25%, 1 = 25–75%, 2 = 76–99%, 3 = complete 
endothelial coverage. Neointimal smooth muscle 
score representing neointimal maturity, estimates 
the proportion of neointimal areas containing 
smooth muscle cells: 0 = no smooth muscle cells 
visible, 1 = < 25%, 2 = 25–75%, 3 = > 75% of 
neointima containing smooth muscle. Each strut in 
the section was scored and the mean inflammation 
and injury score for each section was calculated 
and reported.
Statistical analysis
Normally distributed parametric data are ex-
pressed as average and standard deviation, and as me-
dian and interquartile range [IQR] in cases of skewed 
distribution. When equal variance and normality were 
observed, one-way analysis of variance (ANOVA) with 
Student-Newman-Keuls post-ANOVA tests were 
used to test for differences in variables between stent 
types. When either equal variance test or normality 
test failed, Kruskal-Wallis test (with Dunn’s method 
for post-hoc group comparison) was conducted. Tissue 
coverage was estimated through the average number 
of embedded, protruding covered, uncovered and mal-
laposed struts at a stent level. A value of p £ 0.05 was 
considered statistically significant.
Results
Coronary angiography
There were no differences in baseline vessel 
diameters and overstretch ratios expressed as 
balloon to artery ratio in groups designated both 
for 30- and 90-day follow-up (Table 1). At 28 and 
90 days all studied segments and vessels were 
patent, with no signs of thrombosis or in-stent 
restenosis. There were no differences in late lumen 
loss and percent diameter stenosis at 28 days. At 
90 days the late lumen loss was significantly low-
est in the BMS (p = 0.02) when compared to EES.
Optical coherence tomography
The OCT morphometrical results are presented 
in Figure 2. The stent areas were comparable be-
tween groups designated both for short and long-term 
follow up. At 28 days the neointimal thickness was 
significantly lowest in the BP-SES when compared 
to BMS and EES (p < 0.05). There was also a trend 
toward lowest percent area stenosis in the BP-SES 
when compared to BMS and EES (p = 0.082). At 
3 months there were no differences in all OCT mor-
phometric measurements between the groups.
The analysis of stent coverage and apposi-
tion is presented in Table 2. At 28 days follow up, 
there was a trend toward lower proportion of fully 
embedded struts and higher proportion of protrud-
ing, covered struts in the BP-SES when compared 
to BMS and EES (p < 0.05). There were no dif-
ferences between uncovered and malapossed in 
any of the groups. At 90 days, 90% of struts in all 
groups were embedded and did not differ signifi-
cantly between groups. The rate of uncovered stent 
struts was very low, and did not differ significantly 
between groups (Fig. 3).
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Histopathological evaluation
A detailed histopathological analysis is presented 
in the Tables 3 and 4. In all animals the vessel sizes 
were comparable as represented by the IEL and EEL 
areas. At 28 days, all vessels were patent with no bina-
ry in-stent restenosis or thrombus. The percent area 
stenosis was lowest in the BP-SES group (p < 0.05 
when compared to BMS). Correspondingly, the mean 
neointimal thickness was lowest in the BP-SES 
(p < 0.05 when compared both to EES and BMS). 
Endothelialisation and neointimal maturity expressed 
as smooth muscle cell score were comparable, how-
ever the inflammation score was significantly lower in 
BP-SES and EES when compared to BMS by 70% 
Table 1. Quantitative coronary angiography analysis at baseline, 28 and 90 day follow up.
BP-SES (n = 8) BMS (n = 4) EES (n = 8) P
Baseline
RVD [mm] 2.68 ± 0.4 2.56 ± 0.4 2.49 ± 0.21 0.54
B-2-A 1.2 ± 0.1 1.26 ± 0.1 1.28 ± 0.1 0.23
28 days
MLD [mm] 2.46 ± 0.4 2.28 ± 0.2 2.30 ± 0.5 0.6
%DS 9.85 ± 3.7 8.86 ± 2.4 10.68 ± 5.8 0.8
LL [mm] 0.25 ± 0.2 0.49 ± 0.3 0.36 ± 0.3 0.3
90 days
MLD [mm] 2.48 ± 0.4 2.56 ± 0.3 2.13 ± 0.6 0.2
%DS 10.5 ± 11.2 8.8 ± 3.3 22.3 ± 15 0.07
LL [mm] 0.3 ± 0.23 0.1 ± 0.1* 0.76 ± 0.5 0.02
*p < 0.05 vs. Xience; B-2-A — balloon to artery ratio; BP-SES — biodegradable polymer sirolimus eluting stent; BMS — bare metal stent; 
%DS — percent diameter stenosis; EES — everolimus eluting stent; LL — late lumen loss; MLD — minimal lumen diameter; RVD — reference 
vessel diameter
Figure 2. Optical coherence tomography evaluation depicting morphometric analysis of neointimal thickness, stent 
area and percent area stenosis (AS) at 28 (upper panel) and 90 day follow-up (lower panel); BP-SES — biodegradable 
polymer sirolimus eluting stent; BMS — bare metal stent; EES — everolimus eluting stent.
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and 40%, respectively. On the other hand, the fibrin 
deposition was nearly absent in BMS and reported 
in both DES (p < 0.05). The key findings of the 
histopathological analysis are presented in Figure 4, 
whereas the representative peri-strut magnification 
and stent cross section photomicrographs are shown 
in Figure 5.
At 90 days neointimal hyperplasia expressed 
as percent area stenosis and neointimal thickness 
was comparable among groups. The healing was 
Table 2. Optical coherence tomography stent and vessel morphometry analysis at 28 and 90 days  
follow up. 
Per-stent analysis BP-SES (n = 8) (%) EES (n = 8) (%) BMS (n = 4) (%) P
28 days
Embedded 78.2 ± 24 95.4 ± 7 94.2 ± 4 0.11
Protruding covered 14.8 ± 10* 4.1 ± 4 3.7 ± 6 0.03
Protruding uncovered 6.8 ± 15.7 1.5 ± 3 0.7 ± 1 0.51
Malapposed 0.1 ± 0.3 0.1 ± 0.2 0 0.78
90 days
Embedded 86.7 ± 18 85.1 ± 20 91.3 ± 8 0.75
Protruding covered 11.2 ± 16 11.3 ± 15 7.9 ± 8 0.86
Protruding uncovered 1.95 ± 3 3.7 ± 6 0 0.33
Malapposed 0.1 ± 0.2 0 0 0.59
*p = 0.05 vs. Xience; BP-SES — biodegradable polymer sirolimus eluting stent; BMS — bare metal stent; EES — everolimus eluting stent
Figure 3. Optical coherence tomography. Representative stent cross sections; BP-SES — biodegradable polymer 
sirolimus eluting stent; BMS — bare metal stent; EES — everolimus eluting stent.
BP-SES BMS EES
Da
y 
28
Da
y 
90
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nearly complete and comparable between stents 
(Table 4). The key histological parameters are high-
lighted in Supplementary Figure 1 (see journal 
website), whilst representative high resolution 
photomicrographs in Supplementary Figure 2 
(see journal website).
Table 4. Histopathology at 90 days.
Parameters BP-SES  
(n = 8)
BMS  
(n = 4)
EES  
(n = 8)
One-way  
ANOVA: p
Histomorphometry
EEL area [mm2] 8.14 ± 3.31 7.44 ± 1.93 8.23 ± 1.43 0.862
IEL area [mm2] 6.10 ± 1.94 6.29 ± 1.77 7.03 ± 1.31 0.530
Medial area [mm2] 1.87 ± 1.76 1.15 ± 0.23 1.17 ± 0.22 0.678
Intimal area [mm2] 2.36 ± 0.81 2.78 ± 1.35 2.88 ± 1.51 0.691
Luminal area [mm2] 3.69 ± 1.72 3.47 ± 1.32 4.12 ± 1.67 0.776
Area stenosis [%] 40.2 ± 11.8 44.2 ± 15.1 41.1 ± 21.2 0.927
Mean intimal thickness [mm] 0.29 ± 0.11 0.35 ± 0.15 0.36 ± 0.23 0.803
Healing and biocompatibility
Injury score 0.60 ± 0.70 0.78 ± 0.57 0.62 ± 0.66 0.745
Inflammation score 1.04 ± 0.83 1.34 ± 0.88 1.13 ± 0.88 0.656
Fibrin score 0.23 ± 0.18 0.26 ± 0.17 0.26 ± 0.14 0.930
Endothelialization score 1.79 ± 0.40 2.17 ± 0.34 2.11 ± 0.43 0.265
Neointimal smooth muscle score 1.58 ± 0.39 1.75 ± 0.42 1.54 ± 0.47 0.813
BMS — bare metal stent; BP-SES — biodegradable polymer sirolimus eluting stent; EES — everolimus eluting stent; EEL – external elastic 
lamina; IEL – internal elastic lamina
Table 3. Histopathology at 28 days.
Parameters BP-SES  
(n = 8)
BMS  
(n = 4)
EES  
(n = 8)
One-way ANOVA
P Post hoc
Histomorphometry
EEL area [mm2] 8.64 ± 2.09 8.77 ± 1.78 8.82 ± 1.93 0.941 –
IEL area [mm2] 7.39 ± 1.81 7.30 ± 1.46 7.46 ± 1.58 0.928 –
Medial area [mm2] 1.25 ± 0.29 1.47 ± 0.38 1.36 ± 0.37 0.578 –
Neointimal area [mm2] 0.98 ± 0.33 2.27 ± 0.44 1.56 ± 0.55 < 0.001 < 0.001: BP-SES vs. BMS 
0.038: BP-SES vs. EES 
< 0.050: EES vs. BMS
Luminal area [mm2] 6.42 ± 1.93 5.03 ± 1.35 5.90 ± 1.68 0.447 –
Area stenosis [%] 14.1 ± 6.7 31.4 ± 6.8 21.7 ± 9.5 0.014 < 0.05: BP-SES vs. BMS
Mean intimal thickness [mm] 0.11 ± 0.04 0.26 ± 0.06 0.17 ± 0.07 0.002 < 0.001: BP-SES vs. BMS 
< 0.050: EES vs. BMS
Healing and biocompatibility
Injury score 0.21 ± 0.13 0.26 ± 0.14 0.24 ± 0.29 0.687 –
Inflammation score 0.24 ± 0.12 0.77 ± 0.40 0.40 ± 0.14 0.002 0.002: BP-SES vs. BMS 
0.022: EES vs. BMS
Fibrin score 1.18 ± 0.43 0.17 ± 0.22 1.34 ± 0.26 < 0.001 < 0.001: BP-SES  
and EES vs. BMS
Endothelialisation score 2.21 ± 0.39 1.83 ± 0.34 2.17 ± 0.64 0.463 –
Neointimal smooth muscle score 2.00 ± 0.00 2.00 ± 0.27 2.00 ± 0.25 1.000 –
BMS — bare metal stent; BP-SES — biodegradable polymer sirolimus eluting stent; EES — everolimus eluting stent; EEL – external elastic 
lamina; IEL – internal elastic lamina
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Figure 4. Bar charts featuring histopathological analysis of healing and biocompatibility at 28 day follow-up; BP-SES — 
biodegradable polymer sirolimus eluting stent; BMS — bare metal stent; EES — everolimus eluting stent; *p < 0.05: 
BP-SES vs. BMS; #p < 0.050: EES vs. BMS.
Figure 5. Representative high power images of peri-strut magnifications (20×) stained with hematoxylin and eosin 
(lower panel) and stent cross sections stained with Verhoeff-van Gieson (VVG) at 28 day follow-up (upper panel). 
Fibrin depositis (arrow) visible in BP-SES and EES whereas higher neointimal formation and inflammatory response 
visible in BMS; BP-SES — biodegradable polymer sirolimus eluting stent; BMS — bare metal stent; EES — everolimus 
eluting stent.
BP-SES BMS EES
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Discussion
In current study we evaluate in-vivo and 
histopathological vascular response to the novel, 
BP-SES (Alex Plus, Balton) and compare with the 
fluoropolymer everolimus eluting (Xience Pro, 
Abbott) stent in the porcine coronary in-stent 
restenosis model at short and mid-term follow-up. 
At 28 days BP-SES provided superior neointimal 
hyperplasia inhibition when compared to BMS. 
Additionally, there was a tendency toward lower 
neointimal thickness in OCT in BP-SES when 
compared to EES. On the other hand, there was 
a tendency toward improved neointimal coverage in 
EES in OCT. Angiographically, the late lumen loss 
was lowest in BMS, however we believe this is an 
incidental fining, most likely due to low number of 
BMS, low resolution of angiography and reassuring 
results in OCT analysis. In pathology at one month, 
the healing was comparable between EES and BP-
SES and most interestingly the inflammation was 
lowest in both DES when compared to BMS. Oth-
erwise, the fibrin deposition was increased in both 
new generation DES. At 90 days the in-vivo and 
pathological exponents of healing and biocompat-
ibility were comparable and complete in all groups, 
thus confirming the safety of a studied BP-SES. 
Endothelialization was incomplete in all groups, 
but these results were suspected to be related to 
pre-terminal injury to the endothelium by devices 
used for procedures such as OCT, and not to a real 
delay in endothelialisation process. This notion is 
supported by the fact that full endothelialisation 
of the studied BP-SES at 28 days has been shown 
before [19].
Previously, the first generation, durable poly-
mer SES (Cypher, Cordis) showed inferior vascular 
response when compared to new generation DES 
[20] which has later translated into inferior clinical 
outcome. Therefore, to the best of our knowledge 
this is the first study which evaluated the pre-
clinical in-vivo and vascular tissue response to 
a novel generation SES and directly compared the 
healing with current golden standard, the everoli-
mus eluting fluropolymer EES (Xience Pro). This is 
important in translation to already published clini-
cal trials of similar technologies, which have shown 
non-inferior clinical and angiographic outcomes 
between novel generation SES and fluropolymer 
EES with regard to the incidence of major adverse 
cardiac events [5, 10, 21]. 
In current study, the OCT analysis of the 
vascular response at 28 days, showed that the 
neointimial thickness was smaller in BP-SES. We 
can hypothesize that except from the drug released 
this could be due to different drug release kinetics, 
which in BP-SES is faster when compared to EES. 
The strut coverage in OCT, was slightly in-
ferior in BP-SES when compared to fluropolymer 
EES. Importantly this was not associated with 
impaired healing in the histopathological evalu-
ation. The clinical translation of impaired strut 
coverage in OCT is unclear, however up-to date 
the decreased proportion of protruding but covered 
struts has not translated into poorer outcome in 
the clinical setting [10]. The tissue coverage of 
currently evaluated BP-SES (Alex Plus) has been 
also assessed in the setting of a prospective clini-
cal registry, with OCT evaluation at different time 
points [22]. At 3 month follow up the proportion of 
embedded struts was 85.8% and uncovered 10.3% 
whereas at 6-months the number of uncovered 
struts was only 1.5% at 3 months. These propor-
tions resemble current experimental observations 
and validate this pre-clinical model. 
Both DES showed increased fibrin deposition 
when compared to BMS, which is considered 
a fingerprint of drug elution and retention in tis-
sue and has been reported previously [4, 23]. The 
inflammatory reaction to implanted stents in this 
experiment deserves attention and discussion. At 
1 month follow up, the pathological evaluation has 
reported significantly lower inflammation in both 
new generation DES when compared to BMS. This 
has been reported earlier with first generation SES 
[23], however at 3 months the inflammation tended 
to increase, which is contrary to our findings with 
novel generation SES and no inflammation at ter-
minal follow-up. This preferable biocompatibility 
profile of tested EES and SES with very low peri-
strut inflammation at each study point, is supported 
by previously published reports suggesting that 
stent-based delivery of these analogues selectively 
decreases inflammation by clearing macrophages 
by autophagy, an mTOR inhibition-dependent 
mechanism inducing cell death in mammalian cells 
[24]. We believe that lower inflammation caused by 
modern DES is responsible for improved healing 
and lower late and very late stent thrombosis when 
compared to DES [25].
Limitations of the study
The limitations of this study include the nature 
of an experimental preclinical model as a human 
clinical surrogate and utilization of a healthy do-
mestic swine, without underlying disease.
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Conclusions
In this experimental study, new generation, 
biodegradable polymer SES yielded similar heal-
ing and biocompatibility profile, when compared 
to fluoropolymer EES, whereas the inhibition of 
neointimal hyperplasia was in favour for BP-SES. 
The slightly impaired in-vivo stent coverage in 
OCT did not translate into poorer healing and 
biocompatibility in the pathological evaluation. 
Furthermore, both DES showed lower degree of 
inflammation when compared bare metal stents, 
thus supporting the unrestricted use of this tech-
nology in the clinical setting. 
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